MCID: HYP085
MIFTS: 48

Hypothalamic Disease

Categories: Rare diseases, Endocrine diseases, Bone diseases, Neuronal diseases

Aliases & Classifications for Hypothalamic Disease

MalaCards integrated aliases for Hypothalamic Disease:

Name: Hypothalamic Disease 12 15
Hypothalamic Dysfunction 76 53
Hypothalamic Diseases 44 73
Hypothalamic Dysfunction Syndromes 73
Hypothalamic Disorder 55

Classifications:



External Ids:

Disease Ontology 12 DOID:1931
MeSH 44 D007027
ICD10 33 E23.3

Summaries for Hypothalamic Disease

NIH Rare Diseases : 53 Hypothalamic dysfunction refers to a condition in which the hypothalamus is not working properly. The hypothalamus produces hormones that control body temperature, hunger, moods, release of hormones from many glands such as the pituitary gland, sex drive, sleep, and thirst. The signs and symptoms patients have vary depending on the hormones missing. A number of different causes including anorexia, bleeding, genetic disorder, tumors, and more have been linked to hypothalamic dysfunction. Treatment depends on the cause of the hypothalamic dysfunction.

MalaCards based summary : Hypothalamic Disease, also known as hypothalamic dysfunction, is related to prader-willi syndrome and acromegaly. An important gene associated with Hypothalamic Disease is CRH (Corticotropin Releasing Hormone), and among its related pathways/superpathways are TGF-Beta Pathway and G-Beta Gamma Signaling. The drugs Zinc and Menthol have been mentioned in the context of this disorder. Affiliated tissues include pituitary, testes and brain, and related phenotypes are endocrine/exocrine gland and immune system

Wikipedia : 76 Hypopituitarism is the decreased (hypo) secretion of one or more of the eight hormones normally produced... more...

Related Diseases for Hypothalamic Disease

Diseases related to Hypothalamic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Related Disease Score Top Affiliating Genes
1 prader-willi syndrome 28.0 GH1 GNRH1 POMC
2 acromegaly 27.3 GH1 GHRH POMC PRL
3 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 12.3
4 rohhad 11.9
5 shapiro syndrome 11.0
6 fryns microphthalmia syndrome 11.0
7 x-linked lissencephaly with abnormal genitalia 10.9
8 froelich syndrome 10.7
9 melancholia 10.4 CRH PRL
10 postpartum depression 10.4 CRH PRL
11 endometriosis of uterus 10.3 GNRH1 PRL
12 hypogonadotropism 10.3 GNRH1 PRL
13 fibrous dysplasia/mccune-albright syndrome 10.2 GH1 PRL
14 hypothalamic adipsic hypernatraemia syndrome 10.2
15 tsh producing pituitary tumor 10.2 GH1 PRL
16 anovulation 10.2 GNRH1 PRL
17 pseudohypoparathyroidism, type ia 10.2 GH1 PRL
18 pituitary adenoma 1, multiple types 10.2 GH1 PRL
19 varicocele 10.2 GNRH1 PRL
20 tetrahydrobiopterin deficiency 10.2 GH1 PRL
21 pituitary stalk interruption syndrome 10.1 GH1 PRL
22 mccune-albright syndrome 10.1 GH1 PRL
23 fibrous dysplasia 10.1 GH1 PRL
24 isolated growth hormone deficiency, type ib 10.1 GH1 GHRH
25 aromatase deficiency 10.1 GH1 GNRH1
26 reproductive system disease 10.1 GNRH1 PRL
27 precocious puberty 10.1 GH1 GNRH1
28 isolated growth hormone deficiency, type ii 10.1 GH1 GHRH
29 isolated growth hormone deficiency 10.0 GH1 GHRH
30 acth deficiency, isolated 10.0 CRH POMC
31 fasting hypoglycemia 10.0 CRH POMC
32 adrenal cortical hypofunction 10.0 CRH POMC
33 withdrawal disorder 10.0 CRH POMC
34 ectopic cushing syndrome 10.0 CRH POMC
35 persistent fetal circulation syndrome 10.0 CRH POMC
36 dwarfism 10.0 GH1 GHRH
37 growth hormone deficiency 10.0 GH1 GHRH
38 hypoadrenocorticism, familial 9.9 CRH POMC
39 central nervous system organ benign neoplasm 9.9 POMC PRL
40 premature ovarian failure 1 9.9 GNRH1 PRL
41 mental depression 9.9 CRH POMC
42 hyperthyroidism 9.9 GH1 PRL
43 adrenal adenoma 9.9 CRH POMC
44 gynecomastia 9.9 POMC PRL
45 ovarian disease 9.9 GNRH1 PRL
46 thyroid gland disease 9.8 POMC PRL
47 adrenal rest tumor 9.8 GNRH1 POMC
48 organ system benign neoplasm 9.8 POMC PRL
49 adrenal carcinoma 9.8 CRH POMC
50 endocrine pancreas disease 9.8 GHRH POMC

Graphical network of the top 20 diseases related to Hypothalamic Disease:



Diseases related to Hypothalamic Disease

Symptoms & Phenotypes for Hypothalamic Disease

MGI Mouse Phenotypes related to Hypothalamic Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.55 CRH GHRH GNRH1 POMC PRL
2 immune system MP:0005387 9.35 CRH GHRH GNRH1 POMC PRL
3 liver/biliary system MP:0005370 9.02 CRH GHRH GNRH1 POMC PRL

Drugs & Therapeutics for Hypothalamic Disease

Drugs for Hypothalamic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 325)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Not Applicable,Early Phase 1 7440-66-6 23994
2
Menthol Approved Phase 4 2216-51-5 16666
3
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-23-7 5754
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
5
Cabergoline Approved Phase 4,Phase 3,Phase 2,Not Applicable 81409-90-7 54746
6
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
7
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
8
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83150-76-9 383414 6400441
9 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
10
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
13
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
14
Quinagolide Approved, Investigational Phase 4 97805-50-0, 87056-78-8 105105
15 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 979-32-8
16
Morphine Approved, Investigational Phase 4 57-27-2 5288826
17
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
18
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
19
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
20
Acetaminophen Approved Phase 4 103-90-2 1983
21
Ibuprofen Approved Phase 4 15687-27-1 3672
22
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
23
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-28-2 5757
24
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
25
Cosyntropin Approved Phase 4 16960-16-0 16129617
26
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Not Applicable 28014-46-2
27
Sulfamethoxazole Approved Phase 4 723-46-6 5329
28
Metformin Approved Phase 4 657-24-9 14219 4091
29
Cefazolin Approved Phase 4 25953-19-9 656510 33255
30
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
31
Cefdinir Approved Phase 4 91832-40-5 6915944
32
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
33
Liraglutide Approved Phase 4 204656-20-2 44147092
34
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
35
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
36
leucovorin Approved, Nutraceutical Phase 4,Phase 1 58-05-9 143 6006
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
38
Butyric Acid Experimental, Investigational Phase 4,Not Applicable,Early Phase 1 107-92-6 264
39
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-86-4 3871
40 insulin Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
41 glucocorticoids Phase 4,Phase 2,Phase 1,Not Applicable
42 Dopamine agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Respiratory System Agents Phase 4,Not Applicable
44 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
46 Adrenergic Agonists Phase 4,Phase 3,Not Applicable
47 Adrenergic alpha-Agonists Phase 4,Phase 3,Not Applicable
48 Mitogens Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
49 Adrenergic beta-Agonists Phase 4,Not Applicable
50 Serotonin 5-HT2 Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 553)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
3 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Unknown status NCT02314676 Phase 4
4 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
5 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
6 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
7 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
8 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
9 Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection Completed NCT01652495 Phase 4 methylprednisolone acetate;Triamcinolone Acetonide
10 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
11 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
12 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
13 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
14 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Completed NCT02311894 Phase 4 Somatropin
15 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Completed NCT00851942 Phase 4 Synacthen (Tetracosactrin)
16 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
17 GH and Cardiovascular Risk Factors Completed NCT01877512 Phase 4 Change in daily dosage of Growth Hormone
18 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
19 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
20 Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) Completed NCT01605331 Phase 4 sustained-release recombinant human GH (SR-rhGH)
21 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4 somatropin;placebo
22 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
23 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
24 Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome? Completed NCT01298180 Phase 4 Growth hormone (Genotonorm® or Omnitrope®)
25 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
26 A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Completed NCT01157793 Phase 4 r-hGH;r-hGH
27 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
28 Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Completed NCT00990340 Phase 4
29 Growth Hormone and Glucose Metabolism Completed NCT00929799 Phase 4 recombinant human Growth Hormone (Genotropin® )
30 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
31 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
32 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4 Lanreotide-Autogel 120 mg
33 Acute Application of Pegvisomant and Octreotide in Acromegaly Completed NCT00595140 Phase 4 pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
34 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
35 Easypod United States User Trial Completed NCT00689260 Phase 4
36 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
37 Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT00567385 Phase 4 somatropin
38 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
39 Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency Completed NCT00490191 Phase 4 Somatropin
40 Growth Hormone and Endothelial Function in Children Completed NCT00373386 Phase 4 growth hormone
41 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
42 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
43 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment
44 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
45 Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation Completed NCT00360074 Phase 4 Thyroxin, Triiodothyronine
46 Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Completed NCT00145405 Phase 4 Lanreotide Autogel and Octreotide LAR
47 Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® Completed NCT00256126 Phase 4 Saizen;Saizen
48 A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Completed NCT00212758 Phase 4 Nutropin AQ
49 IGF1 Generation Test Completed NCT00145457 Phase 4
50 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia Completed NCT00140413 Phase 4 Nutropin AQ

Search NIH Clinical Center for Hypothalamic Disease

Cochrane evidence based reviews: hypothalamic diseases

Genetic Tests for Hypothalamic Disease

Anatomical Context for Hypothalamic Disease

MalaCards organs/tissues related to Hypothalamic Disease:

41
Pituitary, Testes, Brain, Bone, Hypothalamus, Heart, Liver

Publications for Hypothalamic Disease

Articles related to Hypothalamic Disease:

(show top 50) (show all 60)
# Title Authors Year
1
Hypothalamic Dysfunction in Obesity and Metabolic Disorders. ( 28933062 )
2017
2
Case of Werner syndrome complicated by adrenal insufficiency due to hypothalamic dysfunction. ( 28240455 )
2017
3
Psychiatric Symptoms in Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome and its Treatment: A Case Report. ( 26830999 )
2016
4
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome and celiac disease in a 13-year-old girl: further evidence for autoimmunity? ( 26352082 )
2016
5
Hypoventilation improvement in an adult non-invasively ventilated patient with Rapid-onset Obesity with Hypothalamic Dysfunction Hypoventilation and Autonomic Dysregulation (ROHHAD). ( 29543408 )
2016
6
Chordoid glioma: A new paradigm of hypothalamic dysfunction? ( 27798757 )
2016
7
Rapid-onset obesity, hypoventilation, hypothalamic dysfunction, autonomic dysregulation syndrome. ( 26229761 )
2015
8
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD): Response to ventilatory challenges. ( 25776886 )
2015
9
Preliminary results on CSF biomarkers for hypothalamic dysfunction in Kleine-Levin syndrome. ( 25454350 )
2015
10
Rapid-Onset Obesity With Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD) Syndrome May Have a Hypothalamus-Periaqueductal Gray Localization. ( 25746964 )
2015
11
Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD): exome sequencing of trios, monozygotic twins and tumours. ( 26302956 )
2015
12
Implications of mitochondrial dynamics on neurodegeneration and on hypothalamic dysfunction. ( 26113818 )
2015
13
Pituitary and/or hypothalamic dysfunction following moderate to severe traumatic brain injury: Current perspectives. ( 26693424 )
2015
14
Gut-Brain: Major Depressive Disorder, Hypothalamic Dysfunction, and High Calcium Score Associated With Leaky Gut. ( 26348609 )
2015
15
Severe phenotype of rapid-onset obesity, hypoventilation, hypothalamic dysfunction, and autonomic dysfunction syndrome. ( 24492667 )
2014
16
Intrathecal synthesis of oligoclonal bands in rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome: new evidence supporting immunological pathogenesis. ( 23292759 )
2014
17
Transgenic mice overexpressing amyloid precursor protein exhibit early metabolic deficits and a pathologically low leptin state associated with hypothalamic dysfunction in arcuate neuropeptide Y neurons. ( 24990930 )
2014
18
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation: review and update. ( 24914877 )
2014
19
Hypothalamic Dysfunction of the Thrombospondin Receptor I+2I'-1 Underlies the Overeating and Obesity Triggered by Brain-Derived Neurotrophic Factor Deficiency. ( 24403154 )
2014
20
Hypothalamic Dysfunction Without Hamartomas Causing Gelastic Seizures in Optic Nerve Hypoplasia. ( 24700666 )
2014
21
Reversible hypothalamic dysfunction in optic nerve germinoma. ( 23524717 )
2013
22
A case of rapid-onset obesity with hypothalamic dysfunction, hypoventilation, autonomic dysregulation, and neural crest tumor: ROHHADNET syndrome. ( 23186956 )
2013
23
Commentary: Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD): Remember Your ABCs (Airway, Breathing, Circulation). ( 23970914 )
2013
24
Comparison of body composition, basal metabolic rate and metabolic outcomes of adults with Prader Willi syndrome or lesional hypothalamic disease, with primary obesity. ( 23318724 )
2013
25
Systemic effects of hypothermia due to hypothalamic dysfunction after resection of a craniopharyngioma: case report and review of literature. ( 23047234 )
2013
26
Nocturnal Anxiety in a Youth with Rapid-onset Obesity, Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD). ( 23970913 )
2013
27
Anesthetic considerations for rapid-onset obesity, hypoventilation, hypothalamic dysfunction, and autonomic dysfunction (ROHHAD) syndrome in children. ( 22862685 )
2013
28
Noninvasive ventilation in a child with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD). ( 23059524 )
2012
29
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation (ROHHAD): a case with additional features and review of the literature. ( 22715259 )
2011
30
Hypothalamic dysfunction in a female with isolated hypogonadotropic hypogonadism and compound heterozygous TACR3 mutations and clinical manifestation in her heterozygous mother. ( 20395662 )
2010
31
Hypogonadism in females with Prader-Willi syndrome from infancy to adulthood: variable combinations of a primary gonadal defect and hypothalamic dysfunction. ( 19946044 )
2010
32
A case of late-onset central hypoventilation syndrome with hypothalamic dysfunction: through a new phenotype. ( 20560260 )
2010
33
Trilateral retinoblastoma with pituitary-hypothalamic dysfunction. ( 18766991 )
2008
34
Delineation of late onset hypoventilation associated with hypothalamic dysfunction syndrome. ( 18670370 )
2008
35
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation presenting in childhood. ( 17606542 )
2007
36
Serum leptin and leptin binding activity in children and adolescents with hypothalamic dysfunction. ( 12199340 )
2002
37
Idiopathic hypothalamic dysfunction with precocious puberty and adipsic hypernatremia first presenting in adolescence. ( 11592577 )
2001
38
Chronic hypernatremia derived from hypothalamic dysfunction: impaired secretion of arginine vasopressin and enhanced renal water handling. ( 11456273 )
2001
39
Hypothalamic dysfunction with polydactyly and hypoplastic nails. ( 10522347 )
1999
40
Hypothalamic dysfunction in "cured" acromegaly is treatment modality dependent. ( 9589676 )
1998
41
Hypothalamic dysfunction in acute head-injured patients with stress ulcer. ( 9796199 )
1998
42
Hypothalamic disease: neurosecretory dysfunction and parasellar lesions. ( 9174692 )
1997
43
Isolated combined growth hormone and gonadotrophin deficiency due to hypothalamic dysfunction, associated with insulin resistance. ( 7554320 )
1995
44
Hypothalamic dysfunction in Parkinson's disease patients. ( 7638039 )
1994
45
Amenorrhea in anorexia nervosa. Neuroendocrine control of hypothalamic dysfunction. ( 7920581 )
1994
46
Neurologic manifestations of hypothalamic disease. ( 1480755 )
1992
47
Hypothalamic disease in association with dysgenesis of the corpus callosum. ( 2813236 )
1989
48
Septic shock with hyperglycemia induced by hypothalamic dysfunction after removal of large parasagittal meningioma. ( 3419486 )
1988
49
Episodic hormone secretion during sleep in Kleine-Levin syndrome: evidence for hypothalamic dysfunction. ( 3477962 )
1987
50
Hypothalamic disease presenting as amenorrhoea: value of computed tomography. ( 4084469 )
1985

Variations for Hypothalamic Disease

Expression for Hypothalamic Disease

Search GEO for disease gene expression data for Hypothalamic Disease.

Pathways for Hypothalamic Disease

Pathways related to Hypothalamic Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.97 GH1 GHRH GNRH1 PRL
2
Show member pathways
12.43 CRH GH1 GHRH POMC
3
Show member pathways
12.37 CRH GH1 GHRH GNRH1 POMC PRL
4
Show member pathways
12.2 GH1 GHRH GNRH1
5
Show member pathways
11.56 GH1 GHRH GNRH1
6 11.5 CRH GHRH POMC
7 11.45 CRH POMC
8 11.37 POMC PRL
9
Show member pathways
10.93 GH1 PRL
10 9.8 CRH POMC

GO Terms for Hypothalamic Disease

Cellular components related to Hypothalamic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.43 CRH GH1 GHRH GNRH1 POMC PRL
2 endosome lumen GO:0031904 9.16 GH1 PRL
3 extracellular space GO:0005615 9.1 CRH GH1 GHRH GNRH1 POMC PRL

Biological processes related to Hypothalamic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.73 CRH GHRH GNRH1 POMC
2 positive regulation of cell proliferation GO:0008284 9.65 CRH GHRH PRL
3 cell-cell signaling GO:0007267 9.58 GHRH GNRH1 POMC
4 response to nutrient levels GO:0031667 9.46 GH1 PRL
5 positive regulation of multicellular organism growth GO:0040018 9.37 GH1 GHRH
6 positive regulation of JAK-STAT cascade GO:0046427 9.32 GH1 PRL
7 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.26 GH1 PRL
8 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.16 GH1 GHRH
9 female pregnancy GO:0007565 9.13 CRH GNRH1 PRL
10 regulation of signaling receptor activity GO:0010469 9.02 GH1 GHRH GNRH1 POMC PRL

Molecular functions related to Hypothalamic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.16 CRH POMC
2 hormone activity GO:0005179 9.02 CRH GH1 GNRH1 POMC PRL
3 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hypothalamic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....